844431-60-3

Basic information

• Product Name: 1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE
• Synonyms: 1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE
• CAS NO: 844431-60-3
• Molecular Formula: C₁₃H₁₉BrN₂
• Molecular Weight: 283.20736
• Mol File: 844431-60-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE(844431-60-3)
• EPA Substance Registry System: 1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE(844431-60-3)

Safety Data

• Hazardous Substances Data: 844431-60-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE is used as a chemical intermediate for the production of various pharmaceutical drugs. Its unique structure and pharmacological properties make it a valuable component in the development of new medications.
Used in Research and Development:
In the field of medicinal chemistry, 1-(4-BROMO-PHENYL)-4-ISOPROPYL-PIPERAZINE serves as a key compound in the research and development of novel pharmaceuticals. Its potential use as a pharmaceutical ingredient is being explored for its ability to contribute to the therapeutic effects of medications.

Upstream product

• 67-64-1 acetone 

Downstream Products

• 844431-49-8 1-[4-(4-isopropyl-piperazin-1-yl)-phenyl]-6-methoxy-2-(3-methoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline 

Relevant articles and documents

Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERα-selective tetrahydroisoquinoline ligands

We disclose herein the discovery of estrogen receptor α (ERα) selective estrogen receptor modulators (SERMs) of the tetrahydroisoquinoline series that incorporate novel conformationally restricted side chains as replacement of the aminoethoxy residue typical of SERMs. Molecular modeling studies used in conjunction with the X-ray crystal structure of the ERα ligand binding domain (LBD) with raloxifene (7) suggested a diazadecaline moiety as a viable mimic of the SERM side chain. On the basis of this knowledge, the piperidinylethoxy moiety of our lead compound 60 was replaced by a diazadecaline subunit, providing the novel tetrahydroisoquinoline 29. In addition to exhibiting a binding affinity to ERα and antagonistic properties in the estrogen response element and MCF-7 assays similar to those of the parent compound 60, ligand 29 showed a reduced agonist behavior in the MCF-7 assay in the absence of 17β-estradiol. These data point toward the fact that 29 may have a potential for breast cancer prevention/treatment in vivo, a feature which is particularly attractive in the quest for safe alternatives to hormone replacement therapy. In a pharmacokinetic experiment carried out in rats, 29 displayed an interesting profile, with a bioavailability of 49%. We also disclose the X-ray crystal structure of 29 in complex with ERα-LBD, which reveals the preferred configurations of 29 at the two chiral centers and the details of its interactions with the receptor. Finally, our structure-activity relationship studies show that other analogues bearing constrained side chains retain potency and antagonist activity and that a 3-OH substituted phenyl D-ring increases the selectivity of a set of piperazinyl-containing ligands in favor of ERα over ERβ.